Medicenna Therapeutics Corp. (TSX:MDNA)
Canada · Delayed Price · Currency is CAD 0.3850
-0.0100 (-2.53%)
Jul 6, 2026, 2:08 PM EST
Medicenna Therapeutics Employees
Medicenna Therapeutics had 15 employees as of March 31, 2026. The number of employees decreased by 3 or -16.67% compared to the previous year.
Employees
15
Change (1Y)
-3
Growth (1Y)
-16.67%
Revenue / Employee
n/a
Profits / Employee
-1.23M CAD
Market Cap
36.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 15 | -3 | -16.67% |
| Mar 31, 2025 | 18 | 2 | 12.50% |
| Mar 31, 2024 | 16 | 0 | - |
| Mar 31, 2023 | 16 | -2 | -11.11% |
| Mar 31, 2022 | 18 | 5 | 38.46% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Medicenna Therapeutics News
- 10 days ago - Medicenna Therapeutics FY26 Loss Widens - Nasdaq
- 10 days ago - Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights - GlobeNewsWire
- 10 days ago - Medicenna Therapeutics Registration statement: Q4 2026 - Filings
- 10 days ago - Medicenna Therapeutics Registration statement: Q4 2026 - Filings
- 25 days ago - Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms - GlobeNewsWire
- 4 weeks ago - Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026 - GlobeNewsWire
- 5 weeks ago - Medicenna Therapeutics Transcript: Lytham Partners Spring 2026 Investor Conference - Transcripts
- 5 weeks ago - Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs - GlobeNewsWire